Developing therapies for heart failure withpreservedejection fraction. Current state and future directions

JACC: Heart Failure

Volumn 2, Issue 2, 2014, Pages 97-112

  Butler, Javed ^a   Fonarow, Gregg C ^b   Zile, Michael R ^c,z   Lam, Carolyn S ^d   Roessig, Lothar ^e   Schelbert, Erik B ^f   Shah, Sanjiv J ^g   Ahmed, Ali ^h   Bonow, Robert O ^g   Cleland, John G F ⁱ   Cody, Robert J ^j   Chioncel, Ovidiu ^k   Collins, Sean P ^l   Dunnmon, Preston ^m   Filippatos, Gerasimos ⁿ   Lefkowitz, Martin P ^o   Marti, Catherine N ^a   McMurray, John J ^p   Misselwitz, Frank ^e   Nodari, Savina ^q   O'Connor, Christopher ^r   Pfeffer, Marc A ^s   Pieske, Burkert ^t   Pitt, Bertram ^u   Rosano, Giuseppe ^v   Sabbah, Hani N ^w   Senni, Michele ^x   Solomon, Scott D ^s   Stockbridge, Norman ^m   Teerlink, John R ^y   Georgiopoulou, Vasiliki V ^a   Gheorghiade, Mihai ^g   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e BAYER PHARMA AG   (Germany)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ CASTLE HILL HOSPITAL   (United Kingdom)

^j JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^k UMF Carol Davila   (Romania)

^l VANDERBILT UNIVERSITY   (United States)

^m CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

ⁿ NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^o NOVARTIS PHARMA AG   (Switzerland)

^p UNIVERSITY OF GLASGOW   (United Kingdom)

^q UNIVERSITY OF BRESCIA   (Italy)

^r DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^s BRIGHAM AND WOMEN S HOSPITAL   (United States)

^t MEDICAL UNIVERSITY OF GRAZ   (Austria)

^u UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^v University of Study of Roma San Raffaele   (Italy)

^w HENRY FORD HOSPITAL   (United States)

^x PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^y UNIVERSITY OF CALIFORNIA   (United States)

^z RALPH H JOHNSON VA MEDICAL CENTER   (United States)

more..

Author keywords

Epidemiology; Heart failure; Preserved ejection fraction; Prognosis; Treatment

Indexed keywords

BIOLOGICAL MARKER; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NATRIURETIC FACTOR; RELAXIN; SILDENAFIL; SPIRONOLACTONE;

ARTERIAL STIFFNESS; CLINICAL FEATURE; CLINICAL PROTOCOL; COMORBIDITY; DIASTOLIC DYSFUNCTION; DISEASE MODEL; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HEMODYNAMICS; HEART LEFT ATRIUM; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE; HEART VENTRICLE REMODELING; HUMAN; KINESIOTHERAPY; NEEDS ASSESSMENT; NONHUMAN; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CAPACITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; EXERCISE TOLERANCE; FOOD AND DRUG ADMINISTRATION; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HOSPITALIZATION; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PULMONARY VASCULAR DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC DYSFUNCTION; ANIMAL; DIASTOLE; ECHOCARDIOGRAPHY; ETIOLOGY; FORECASTING; HEART ATRIUM; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; PHYSIOLOGY; SYSTOLE; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIASTOLE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FORECASTING; HEART ATRIA; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; STROKE VOLUME; SYSTOLE; TREATMENT OUTCOME; VASCULAR STIFFNESS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84897487563     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.10.006     Document Type: Review

References (93)

1. Steinberg B.A., Zhao X., Heidenreich P.A., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012, 126:65-75.
2. Philbin E.F., Rocco T.A., Lindenmuth N.W., Ulrich K., Jenkins P.L. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000, 109:605-613.
3. Vasan R.S., Larson M.G., Benjamin E.J., Evans J.C., Reiss C.K., Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. JAm Coll Cardiol 1999, 33:1948-1955.
4. Yancy C.W., Lopatin M., Stevenson L.W., De Marco T., Fonarow G.C. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. JAm Coll Cardiol 2006, 47:76-84.
5. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355:251-259.
6. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. NEngl J Med 2006, 355:260-269.
7. Fonarow G.C., Stough W.G., Abraham W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. JAm Coll Cardiol 2007, 50:768-777.
8. Solomon S.D., Anavekar N., Skali H., et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005, 112:3738-3744.
9. Campbell R.T., Jhund P.S., Castagno D., Hawkins N.M., Petrie M.C., McMurray J.J. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?. JAm Coll Cardiol 2012, 60:2349-2356.
10. Zile M.R., Gaasch W.H., Anand I.S., et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010, 121:1393-1405.
11. Farr M.J., Lang C.C., Lamanca J.J., et al. Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol 2008, 102:203-206.
12. Lewis E.F., Lamas G.A., O'Meara E., et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail 2007, 9:83-91.
13. Aronow W.S., Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993, 71:602-604.
14. Aronow W.S., Ahn C., Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or= 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997, 80:207-209.
15. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
16. Cleland J.G., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
17. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. NEngl J Med 2008, 359:2456-2467.
18. Yip G.W., Wang M., Wang T., et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008, 94:573-580.
19. Kitzman D.W., Hundley W.G., Brubaker P.H., et al. Arandomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail 2010, 3:477-485.
20. Setaro J.F., Zaret B.L., Schulman D.S., Black H.R., Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990, 66:981-986.
21. Hung M.J., Cherng W.J., Kuo L.T., Wang C.H. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract 2002, 56:57-62.
22. Nodari S., Metra M., Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003, 5:621-627.
23. Bergstrom A., Andersson B., Edner M., Nylander E., Persson H., Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004, 6:453-461.
24. Mottram P.M., Haluska B., Leano R., Cowley D., Stowasser M., Marwick T.H. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004, 110:558-565.
25. Ahmed A., Rich M.W., Fleg J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006, 114:397-403.
26. Deswal A., Richardson P., Bozkurt B., Mann D.L. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). JCard Fail 2011, 17:634-642.
27. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.
28. Redfield M.M., Chen H.H., Borlaug B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013, 309:1268-1277.
29. Conraads V.M., Metra M., Kamp O., et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012, 14:219-225.
30. Yamamoto K., Origasa H., Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013, 15:110-118.
31. Solomon S.D., Zile M., Pieske B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012, 380:1387-1395.
32. Kitzman D.W., Brubaker P.H., Morgan T.M., Stewart K.P., Little W.C. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 2010, 3:659-667.
33. Edelmann F., Gelbrich G., Dungen H.D., et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. JAm Coll Cardiol 2011, 58:1780-1791.
34. Smart N.A., Haluska B., Jeffriess L., Leung D. Exercise training in heart failure with preserved systolic function: a randomized controlled trial of the effects on cardiac function and functional capacity. Congest Heart Fail 2012, 18:295-301.
35. Haykowsky M.J., Brubaker P.H., Stewart K.P., Morgan T.M., Eggebeen J., Kitzman D.W. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. JAm Coll Cardiol 2012, 60:120-128.
36. Fujimoto N., Prasad A., Hastings J.L., et al. Cardiovascular effects of 1year of progressive endurance exercise training in patients with heart failure with preserved ejection fraction. Am Heart J 2012, 164:869-877.
37. Kitzman D.W., Brubaker P.H., Herrington D.M., et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: arandomized, controlled, single-blind trial. JAm Coll Cardiol 2013, 62:584-592.
38. Borlaug B.A., Olson T.P., Lam C.S., et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. JAm Coll Cardiol 2010, 56:845-854.
39. Maeder M.T., Thompson B.R., Brunner-La Rocca H.P., Kaye D.M. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. JAm Coll Cardiol 2010, 56:855-863.
40. Paulus W.J. Culprit mechanism(s) for exercise intolerance in heart failure with normal ejection fraction. JAm Coll Cardiol 2010, 56:864-866.
41. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007, 115:1982-1990.
42. van Heerebeek L., Borbely A., Niessen H.W., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113:1966-1973.
43. Kotter S., Gout L., Von Frieling-Salewsky M., et al. Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts. Cardiovasc Res 2013, 99:648-656.
44. Chung C.S., Hutchinson K.R., Methawasin M., et al. Shortening of the elastic tandem immunoglobulin segment of titin leads to diastolic dysfunction. Circulation 2013, 128:19-28.
45. Borlaug B.A., Nishimura R.A., Sorajja P., Lam C.S., Redfield M.M. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010, 3:588-595.
46. Bruch C., Stypmann J., Grude M., Gradaus R., Breithardt G., Wichter T. Left bundle branch block in chronic heart failure-impact on diastolic function, filling pressures, and B-type natriuretic peptide levels. JAm Soc Echocardiogr 2006, 19:95-101.
47. Borlaug B.A., Kass D.A. Ventricular-vascular interaction in heart failure. Heart Fail Clin 2008, 4:23-36.
48. Shah S.J. Evolving approaches to the management of heart failure with preserved ejection fraction in patients with coronary artery disease. Curr Treat Options Cardiovasc Med 2010, 12:58-75.
49. Tamarappoo B.K., John B.T., Reinier K., et al. Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluation. JAm Heart Assoc 2012, 1:e001511.
50. Thum T., Gross C., Fiedler J., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
51. Persson H., Lonn E., Edner M., et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. JAm Coll Cardiol 2007, 49:687-694.
52. Zile M.R., Gottdiener J.S., Hetzel S.J., et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011, 124:2491-2501.
53. Melenovsky V., Borlaug B.A., Rosen B., et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. JAm Coll Cardiol 2007, 49:198-207.
54. O'Rourke M.F., Staessen J.A., Vlachopoulos C., Duprez D., Plante G.E. Clinical applications of arterial stiffness;definitions and reference values. Am J Hypertens 2002, 15:426-444.
55. Redfield M.M., Jacobsen S.J., Borlaug B.A., Rodeheffer R.J., Kass D.A. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 2005, 112:2254-2262.
56. Balmain S., Padmanabhan N., Ferrell W.R., Morton J.J., McMurray J.J. Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function. Eur J Heart Fail 2007, 9:865-871.
57. Akiyama E., Sugiyama S., Matsuzawa Y., et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. JAm Coll Cardiol 2012, 60:1778-1786.
58. Lam C.S., Brutsaert D.L. Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction. JAm Coll Cardiol 2012, 60:1787-1789.
59. Borlaug B.A., Kass D.A. Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med 2006, 16:273-279.
60. Guazzi M., Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol 2010, 7:648-659.
61. Abel F.L., Waldhausen J.A. Effects of alterations in pulmonary vascular resistance on right ventricular function. JThorac Cardiovasc Surg 1967, 54:886-894.
62. Morris D.A., Gailani M., Vaz Perez A., et al. Right ventricular myocardial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. JAm Soc Echocardiogr 2011, 24:886-897.
63. Ather S., Chan W., Bozkurt B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. JAm Coll Cardiol 2012, 59:998-1005.
64. Mohammed S.F., Borlaug B.A., Roger V.L., et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail 2012, 5:710-719.
65. Lam C.S., Lyass A., Kraigher-Krainer E., et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 2011, 124:24-30.
66. McManus D.D., Hsu G., Sung S.H., et al. Atrial fibrillation andoutcomes in heart failure with preserved versus reduced left ventricular ejection fraction. JAm Heart Assoc 2013, 2:e005694.
67. Paulus W.J., Tschope C. Anovel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. JAm Coll Cardiol 2013, 62:263-271.
68. Grewal J., McKelvie R.S., Persson H., et al. Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 2008, 102:733-737.
69. Rossi A., Cicoira M., Florea V.G., et al. Chronic heart failure with preserved left ventricular ejection fraction: diagnostic and prognostic value of left atrial size. Int J Cardiol 2006, 110:386-392.
70. Ohtani T., Mohammed S.F., Yamamoto K., et al. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. Eur Heart J 2012, 33:1742-1749.
71. Wang M., Yip G.W., Wang A.Y., et al. Tissue Doppler imaging provides incremental prognostic value in patients with systemic hypertension and left ventricular hypertrophy. JHypertens 2005, 23:183-191.
72. Wong T.C., Piehler K., Meier C.G., et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 2012, 126:1206-1216.
73. Wong T.C., Piehler K.M., Kang I.A., et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 2013, June 11 [E-pub ahead of print].
74. Wachter R., Schmidt-Schweda S., Westermann D., et al. Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. Eur Heart J 2009, 30:3027-3036.
75. Abraham W.T., Adamson P.B., Bourge R.C., et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011, 377:658-666.
76. Bourge R.C., Abraham W.T., Adamson P.B., et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. JAm Coll Cardiol 2008, 51:1073-1079.
77. Sweitzer N.K., Lopatin M., Yancy C.W., Mills R.M., Stevenson L.W. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (>or=55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol 2008, 101:1151-1156.
78. Katz S.D., Hryniewicz K., Hriljac I., et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005, 111:310-314.
79. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
80. Yu L., Ruifrok W.P., Meissner M., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
81. Krum H., Elsik M., Schneider H.G., et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 2011, 4:561-568.
82. Anjan V.Y., Loftus T.M., Burke M.A., et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol 2012, 110:870-876.
83. Anand I.S., Rector T.S., Cleland J.G., et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 2011, 4:569-577.
84. Arias M.A., Garcia-Rio F., Alonso-Fernandez A., Mediano O., Martinez I., Villamor J. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation 2005, 112:375-383.
85. Cha Y.M., Wokhlu A., Asirvatham S.J., et al. Success of ablation for atrial fibrillation in isolated left ventricular diastolic dysfunction: a comparison to systolic dysfunction and normal ventricular function. Circ Arrhythm Electrophysiol 2011, 4:724-732.
86. Allen L.A., Gheorghiade M., Reid K.J., et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes 2011, 4:389-398.
87. Teerlink J.R., Cotter G., Davison B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013, 381:29-39.
88. Little W.C., Zile M.R., Kitzman D.W., Hundley W.G., O'Brien T.X., Degroof R.C. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. JCard Fail 2005, 11:191-195.
89. Zile M.R., Bourge R.C., Bennett T.D., et al. Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. JCard Fail 2008, 14:816-823.
90. Orozco-Gutierrez J.J., Castillo-Martinez L., Orea-Tejeda A., et al. Effect of L-arginine or L-citrulline oral supplementation on blood pressure and right ventricular function in heart failure patients with preserved ejection fraction. Cardiol J 2010, 17:612-618.
91. Guazzi M., Vicenzi M., Arena R., Guazzi M.D. Pulmonary hypertensionin heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011, 124:164-174.
92. Desai A.S., Lewis E.F., Li R., et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011, 162:966-972.e10.
93. Maurer M.S., Teruya S., Chakraborty B., Helmke S., Mancini D. Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy. Circ Heart Fail 2013, 6:254-263.